Session » Systemic Sclerosis and Related Disorders – Clinical Poster III

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2716

A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2689

Association between Small Vessel Disease and Arterial Stiffness in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2701

Botulinum Toxin in the Management of Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 2711

Comparison of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis with That Associated with Other Diseases: Are There Differences?

9:00AM-11:00AM: Abstract Number: 2709

Conversion of Normal Mean Pulmonary Arterial Pressure to Pulmonary Hypertension in Systemic Sclerosis – a Longitudinal Observational Study

9:00AM-11:00AM: Abstract Number: 2708

Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers

9:00AM-11:00AM: Abstract Number: 2703

Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis

9:00AM-11:00AM: Abstract Number: 2706

Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2697

Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2712

Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies

9:00AM-11:00AM: Abstract Number: 2692

High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2702

Incidence, Prevalence, Mortality and Comparison of the Acr/EULAR 2013 Classification Criteria with 1980 Criteria in Physician Diagnosed Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)

9:00AM-11:00AM: Abstract Number: 2696

Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California

9:00AM-11:00AM: Abstract Number: 2691

Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis

9:00AM-11:00AM: Abstract Number: 2688

Increased Serum Uric Acid Levels Are Associated with a Higher Risk of Digital Ulcers in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2713

Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?

9:00AM-11:00AM: Abstract Number: 2705

Optimized Protocol for Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2687

Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors

9:00AM-11:00AM: Abstract Number: 2694

Performance of Anti-Scl-70 Antibody Testing By Multiple-Bead, Enzyme-Linked Immunosorbent Assay, and Immunodiffusion in a University Setting

9:00AM-11:00AM: Abstract Number: 2710

Physical Activity Trackers Work Well As a Monitor of Physical Activity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2690

Potential Markers of Skin Involvement in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2704

Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2695

Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry

9:00AM-11:00AM: Abstract Number: 2698

Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 2700

Rescuing Standard Analyses of Immunosuppresive Rescue Therapy in Randomized Controlled Trials: Alternative Approaches in a Scleroderma Clinical Trial

9:00AM-11:00AM: Abstract Number: 2707

Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome

9:00AM-11:00AM: Abstract Number: 2714

Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2715

The Effect of an Intensive Controlled 6-Moth Physical-Occupational Therapy Program with Subsequent 6-Month Follow-up Period in Patients with Systemic Sclerosis – Preliminary Data

9:00AM-11:00AM: Abstract Number: 2699

Using ICD-10 Codes to Identify Patients with Systemic Sclerosis in the Electronic Health Record

9:00AM-11:00AM: Abstract Number: 2693

What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].